With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Eli Lilly and Co.’s chief scientific officer, Daniel Skovronsky, called peresolimab, the PD-1 agonist previously in the works by the firm for rheumatoid arthritis (RA), a “really interesting mechanism ...

Brought to you by Eli LillyFeeling stagnant at work? Hungry for change? Craving something new? Your new career could ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

Lilly Limerick is set to be the global pharmaceutical leader's most technically advanced manufacturing site to date ...

On Wednesday, Eli Lilly and Co (NYSE:LLY) stock plummeted after the company released worse-than-expected third-quarter ...

Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best BofA’s top growth stocks with the fastest projected EPS growth rates. For the ...

My name is Brianna and I will be your conference operator today. At this time, I'd like to welcome everyone to the Kinsale Capital Group, Inc. Third Quarter 2024 Earnings Conference Call.